icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
21 Sep, 2021 13:18

Second dose of J&J Covid jab increases protection to 94%, firm’s data shows

Second dose of J&J Covid jab increases protection to 94%, firm’s data shows

Johnson & Johnson has announced that a second shot of its Covid jab, administered around two months after the first, enhances the protection offered by the vaccine to 94% against moderate and severe cases of the virus in the US.

In a statement issued on Tuesday, the pharmaceutical company released new data showing the increased efficacy of the vaccine after administering a top-up dose, with antibody levels rising four to six times higher than after the first. When given six months after the first dose, however, antibody levels climbed up twelve-fold.

The firm's Chief Scientific Officer Paul Stoffels stressed the importance of the single-shot J&J jab in fighting the global pandemic and “protecting as many people as possible against hospitalization and death.” However, Stoffels praised the recent evidence supporting the booster shot’s enhanced coverage.

As per the statement, the safety profile of the vaccine remained consistent and generally well tolerated as a booster dose.

J&J says it has submitted its data to the US Food and Drug Administration (FDA) and it plans to give its recent findings to the World Health Organization (WHO), as well as other regulators globally.

Also on rt.com FDA advisory panel votes AGAINST vaccine booster shots for all, approves for over-65s and high-risk

On Friday, the FDA recommended third shots of Pfizer’s mRNA vaccine for people at higher risk from coronavirus and citizens over the age of 65. However, the panel stopped short of mass-authorizing boosters of Pfizer’s jab.

Rival mRNA vaccine developer Moderna has also been pushing for boosters, with the firm releasing a study last week to show that its shot’s efficacy wanes over time, making a claim that top-up doses could be beneficial.

The efficacy of the single-shot J&J jab was found to be lower than other vaccines at 66%, according to results from its phase-three trials. Meanwhile, the protection offered by the two-dose mRNA vaccines produced by Pfizer-BioNTech and Moderna stood at 95% and 94.5%, respectively.

Also on rt.com EU drugs regulator recommends flagging new possible adverse reactions to J&J Covid jab on product label

Think your friends would be interested? Share this story!